Our findings indicate that olanzapine promotes hepatic PCSK9 expression by upregulating LXRα, thereby affecting the expression of hepatic lipogenesis-associated genes FAS and SCD1 as well as oxidation-related genes SCAD and PPARα, which results in lipid accumulation and the development of NAFLD. Here, FAS is linked to metabolic dysfunction-associated steatotic liver disease.